NCT03756233View on ClinicalTrials.gov

Gradual Withdrawal of Remifentanil Infusion Reduced Postoperative Pain and Opioid Requirement During Breast Surgery

NACompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

November 26, 2018

Primary Completion Date

July 1, 2019

Study Completion Date

July 3, 2019

Conditions
Pain, Postoperative
Interventions
DRUG

Remifentanil

Remifentanil is a potent, short-acting synthetic opioid analgesic drug. It is given to patients during surgery to relieve pain and as an adjunct to an anesthetic.

Trial Locations (1)

06351

Samsung Medical Center, Seoul

All Listed Sponsors
lead

Samsung Medical Center

OTHER

NCT03756233 - Gradual Withdrawal of Remifentanil Infusion Reduced Postoperative Pain and Opioid Requirement During Breast Surgery | Biotech Hunter | Biotech Hunter